Raymond James Cuts Knight Therapeutics (TSE:GUD) Price Target to C$7.50

Knight Therapeutics (TSE:GUD) had its price target dropped by equities researchers at Raymond James from C$8.00 to C$7.50 in a research note issued on Thursday,BayStreet.CA reports. Raymond James’ price target indicates a potential upside of 45.63% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Knight Therapeutics Price Performance

Shares of GUD stock remained flat at C$5.15 during trading on Thursday. 39,027 shares of the company traded hands, compared to its average volume of 69,259. Knight Therapeutics has a one year low of C$5.07 and a one year high of C$6.23. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. The firm has a market cap of C$521.23 million, a PE ratio of -25.75, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The business’s 50 day simple moving average is C$5.72 and its 200-day simple moving average is C$5.74.

Insider Buying and Selling at Knight Therapeutics

In related news, insider Sime Armoyan sold 300,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00. In other news, Senior Officer Amal Khouri sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of C$5.78, for a total transaction of C$28,919.00. Also, insider Sime Armoyan sold 300,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. 45.62% of the stock is owned by insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.